Fate Therapeutics Inc FATE:NASDAQ

Last Price$18.68NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/11/19

Today's Change-0.23(1.24%)
Bid (Size)$18.32 (1)
Ask (Size)$19.18 (1)
Day Low / High$18.53 - 19.96
Volume1.0 M

View Biotechnology IndustryPeer Comparison as of 12/11/2019


Fate Therapeutics Inc ( NASDAQ )

Price: $18.68
Change: -0.23 (1.24%)
Volume: 1.0 M
4:00PM ET 12/11/2019

Veracyte Inc ( NASDAQ )

Price: $28.68
Change: -0.29 (1.00%)
Volume: 400.6 K
4:00PM ET 12/11/2019

NextCure Inc ( NASDAQ )

Price: $51.55
Change: -1.57 (2.96%)
Volume: 396.0 K
4:00PM ET 12/11/2019

Esperion Therapeutics Inc ( NASDAQ )

Price: $50.13
Change: -0.16 (0.32%)
Volume: 504.5 K
4:00PM ET 12/11/2019

Alector Inc ( NASDAQ )

Price: $19.11
Change: -0.44 (2.25%)
Volume: 167.0 K
4:00PM ET 12/11/2019

Read more news Recent News

Fate Therapeutics Says FT819 Exhibits Enhanced Tumor Clearance in Preclinical Leukemia Trial
11:18AM ET 12/10/2019 MT Newswires

Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said Tuesday that its FT819 treatment exhibited enhanced tumor clearance compared...

Fate Therapeutics Says Data for CAR NK Cell Cancer Immunotherapy Show Durable Anti-Tumor Effect; Stock Up 45%
3:51PM ET 12/09/2019 MT Newswires

Fate Therapeutics' (FATE) shares were up nearly 45% in late-afternoon trading after the company said that new preclinical data for FT596, its multi-antigen...

Analyst Actions: BMO Capital Cuts Fate Therapeutics' Price Target to $22 From $26, Keeps Outperform Rating
12:02PM ET 12/09/2019 MT Newswires

Fate Therapeutics (FATE) has an average rating among analysts of buy, with an average price target of $25. Price: 19.08, Change: +5.41, Percent Change:...

Analyst Actions: Wells Fargo Upgrades Fate Therapeutics to Outperform From Market Perform; Price Target is $24
7:25AM ET 12/09/2019 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $25. Price: 13.67, Change: +0.10, Percent Change: +0.74...

Company Profile

Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Number of Employees104
Recent SEC Filing11/14/20198-K
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Scientific OfficerDaniel D. Shoemaker
Vice President-Clinical DevelopmentYu Waye Chu
Senior Vice President-Corporate DevelopmentJim Beitel

Company Highlights

Price Open$19.04
Previous Close$18.68
52 Week Range$11.00 - 22.82
Market Capitalization$1.4 B
Shares Outstanding75.6 M
SectorHealth Technology
Next Earnings Announcement03/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.31
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-900.24%
Return on Equity-48.94%

Analyst Ratings as of 12/06/2019

Consensus RecommendationConsensus Icon
Powered by Factset